AAV Vector Suspension
Our best-in-class AAV Vector Suspension Platform enables cell and gene therapies to be developed, manufactured, and released faster and with greater predictability
WuXi Advanced Therapies’ integrated single-source, in-house platform – with in-stock raw materials with established batch records, enhanced manufacturing scalability and flexibility, and complete testing capabilities – is a time-sensitive solution that produces high-quality AAV vectors to meet not only your needs but also the requirements of international regulatory agencies.
- Industry-leading experience with robust scalability and consistent predictability.
- Enhanced manufacturing capacity and scheduling flexibility
to meet customer timelines.
- End-to-end integrated solutions with dedicated process and analytical development teams to support feasibility studies, verification runs and tox material production.
- State-of-the-art GMP manufacturing facility with single-use bioreactors ranging up to 1000 L SUB — compliant with US, EU, China and other GMP regulations.
- Security of supply with raw materials and consumables in stock – ready for use – with established batch records.
- Full in-process and release testing, plus complete quality control and characterization services with regulatory support.
- Characterized MCB and WCB ready for client production.
- Consistent product quality and productivity when process is scaled up, and downstream process that typically results in 20-40% overall yield in viral particle.